{
  "ticker": "BB1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967095",
  "id": "02967095",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250708",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06ll2bj9nq5vb3.pdf",
  "summary": "**Summary of ASX Announcement (ASX:BB1) \u2013 Clinical Trial Update:**  \n\n- **Second U.S. Trial Site Added:** University of Nebraska Medical Center (UNMC) confirmed as the second site for BlinkLab\u2019s FDA 510(k) autism diagnostic trial.  \n- **Pilot Phase Progress:** 100-participant pilot nearing completion, results expected this quarter.  \n- **Main Study Expansion:** Planned enrollment of 750\u2013900 children across up to 10 U.S. sites, aiding regulatory submission and future adoption.  \n- **FDA 510(k) Timeline:** Final submission expected in 2026.  \n\n*No material financial, trading, or capital structure impacts identified.*",
  "usage": {
    "prompt_tokens": 1257,
    "completion_tokens": 147,
    "total_tokens": 1404,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T23:33:39.256158"
}